Definition of orphan drug by the EMA
Tuesday March 28th 2023 from 12:30 to 13:30 CET Speaker: [...]
Melorheostosis – Webinar series in rare bone disease
1st part: Tuesday February 7th 2023 from 16:00 to 17:00 [...]
Essential requirement before thinking about a clinical trial
Tuesday February 28th 2023 from 12:00 to 13:00 CET Speakers: Viviana [...]
Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description
Post-authorisation safety study of burosumab use in paediatric, adolescent and [...]
Optimising the diagnosis and referral of achondroplasia in Europe: European Achondroplasia Forum best practice recommendations
Optimising the diagnosis and referral of achondroplasia in Europe: European [...]
More severe phenotype of early-onset osteoporosis associated with recessive form of LRP5 and combination with DKK1 or WNT3A
More severe phenotype of early-onset osteoporosis associated with recessive form [...]
WNT11, a new gene associated with early onset osteoporosis, is required for osteoblastogenesis
WNT11, a new gene associated with early onset osteoporosis, is [...]
Skeletal and extraskeletal disorders of biomineralization
Skeletal and extraskeletal disorders of biomineralization Collins MT et al., [...]
Clinical, Immunological, and Genetic Findings in a Cohort of Patients with the DiGeorge Phenotype without 22q11.2 Deletion
Clinical, Immunological, and Genetic Findings in a Cohort of Patients [...]
Secondary peripheral chondrosarcoma arising in solitary osteochondroma: variables influencing prognosis and survival
Secondary peripheral chondrosarcoma arising in solitary osteochondroma: variables influencing prognosis [...]
Funded by the European Union
“Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.”
